FDA全球物质注册数据库(FDA Global Substance Registration System)
物质名称ZAGOTENEMAB
异名/同义词IMMUNOGLOBULIN G4, ANTI-(TAU PROTEIN) (HUMAN MONOCLONAL LY3303560 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL LY3303560 LIGHT CHAIN, DIMER
IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS MICROTUBULE-ASSOCIATED PROTEIN TAU (NEUROFIBRILLARY TANGLE PROTEIN, PHF-TAU)) HUMANIZED MONOCLONAL ANTIBODY .GAMMA.4 HEAVY CHAIN (1-442) (HUMANIZED VH (HOMO SAPIENS IGHV5-51*01 (85%) (IGHD)-IGHJ4*01 (87%)) (8.8.9) (1-116) -HOMO SAPIENS IGHG4*01 (HINGE(S10>P(224)), CH2(F4>A(230),L5>A(231)), CH3(K107>DEL(443))) (117-442)) (130-219')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-219') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV3-20*01 (79%) IGKJ4*01)(11.3.9) (1'-112') -HOMO SAPIENS IGKC*01 (113'-219')), DIMER (222-222'':225-225'')-BISDISULFIDE
LY3303560
LY-3303560
ZAGOTENEMAB
ZAGOTENEMAB [INN]
ZAGOTENEMAB [USAN]
ZAGOTENEMAB [WHO-DD]
CAS登记号2019133-28-7
物质唯一标识(Unique Ingredient Identifier)AY6V5E2GNX
分子式
国际化合物标识(International Chemical Identifier,InChI)
SMILES
分子结构式
欧洲化学品管理局注册号(ECHA)
成分类型 / INGREDIENT SUBSTANCE
关联数据
  • 药品国际非专利名称数据库
  • 世界卫生组织药物词典
扩展资源
©2006-2026 Drugfuture->FDA Global Substance Registration System